Mirror Biologics is an international biopharmaceutical company headquartered in Tampa, Florida where it conducts advanced bioreactor research and prototype development for commercial manufacturing “pods” and operates a FDA registered 21 CFR 1271-compliant blood donor and cell processing center and a Phase I/II clinical research center. In Jerusalem we operate a GMP cell manufacturing and research facility. We also have clinical and distribution operations in Bangkok, Thailand and Kuala Lumpur, Malaysia. The Mirror Effect technology platform enables reverse engineering of known effective immune responses and imprinting of these immune cascades upon failed immune systems. Mirror Effect is protected by over 200 patents issued worldwide. The lead drug, AlloStim®, is an “off-the-shelf,” non-genetically manipulated, patented, living immune cell differentiated from precursor cells purified from blood of healthy donors and formulated with monoclonal antibody-coated microparticles. The unique feature of AlloStim® is that can imprint a protective or therapeutic cellular immune response that is customized to a patient’s resident disease without the need to have prior knowledge of the type of cancer/virus or genetic properties of the disease. Proprietary “artificial lymph node” bioreactors are designed for high volume, high density scale-up of AlloStim® and novel frozen dosage forms that enable extended shelf life and economical distribution. Mirror Biologics purchased the exclusive, worldwide rights to AlloStim® and the Mirror Effect technology platform from Immunovative Therapies, Ltd, an Israeli company.